Role of 4-1BB:4-1BB ligand in cancer immunotherapy. (Q35606360)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671675%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

review article

1 reference

title

Role of 4-1BB:4-1BB ligand in cancer immunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671675%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671675%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

Adam T C Cheuk

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671675%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Ghulam J Mufti

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671675%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

publication date

1 March 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671675%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671675%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671675%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671675%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

215-226

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671675%20AND%20SRC:MED&resulttype=core&format=json

The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses

21 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Costimulatory regulation of T cell function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

CD28/B7 system of T cell costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Co-stimulation in T cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

T cell co-stimulatory molecules other than CD28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

cDNA sequences of two inducible T-cell genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Molecular and biological characterization of human 4-1BB and its ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

CD137, a member of the tumor necrosis factor receptor family, is located on chromosome 1p36, in a cluster of related genes, and colocalizes with several malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Characterization of human homologue of 4-1BB and its ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Role of 4-1BB in immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Expression of CD137 (4-1BB) on human follicular dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

NF-kappaB and AP-1 regulate activation-dependent CD137 (4-1BB) expression in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Cutting edge: depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Immune responses in 4-1BB (CD137)-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Role of 4-1BB (CD137) in the functional activation of cord blood CD28(-)CD8(+) T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Cutting edge: Expression of functional CD137 receptor by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Viruses as triggers of autoimmunity: facts and fantasies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Therapeutic vaccination with tumor cells that engage CD137.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Tumour rejection by gene transfer of 4-1BB ligand into a CD80(+) murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Expression of co-stimulatory 4-1BB ligand induces significant tumor regression and protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

A new analysis of allogeneic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

A fundamental difference in the capacity to induce proliferation of naive T cells between CD28 and other co-stimulatory molecules

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

Expression characteristics of two potential T cell mediator genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

CD137 activation abrogates granulocyte-macrophage colony-stimulating factor-mediated anti-apoptosis in neutrophils

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

Role of TNF receptor-associated factor 2 and p38 mitogen-activated protein kinase activation during 4-1BB-dependent immune response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

4-1BB co-stimulation enhances human CD8(+) T cell priming by augmenting the proliferation and survival of effector CD8(+) T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

Progressive depletion of peripheral B lymphocytes in 4-1BB (CD137) ligand/I-Ealpha)-transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

New insights into the role of 4-1BB in immune responses: beyond CD8+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

Costimulation of human CD28- T cells by 4-1BB ligand

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

1 reference

7 January 2021

Releasing the brakes on antitumor immune response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-phase I clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9P melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021

Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700670

7 January 2021